Enesi Pharma, a pharmaceutical company developing injectable solid dose drug-device vaccine products, has collaborated with the scientists at the Oxford Vaccine Group of the University of Oxford.

It was reported yesterday that the collaboration is aimed at creating and testing a solid dose vaccine against plague. It will leverage Enesi's ImplaVax needle-free technology and a proprietary vaccine against the bacteria causing plague (Yersinia pestis) developed by Oxford Vaccine Group, based on a ChAdOx adenovirus vector.

The partnership between both parties aims to create a stable and easy-to-use solid dose plague vaccine for use in areas around the world where outbreaks occur and for building strategic stockpiles as part of government preparedness for rapid deployment in the event of a bioterrorism incident.